Evoke Pharma Announces Pricing of Initial Public Offering of 2,100,000 Shares of Common Stock
SAN DIEGO, Sept. 24, 2013 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc., a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the pricing of its initial public offering of 2,100,000 shares of its common stock at a public offering price of $12.00 per share. The gross proceeds to Evoke Pharma from the initial public offering are expected to be $25,200,000, before underwriting discounts and commissions and estimated offering expenses. Evoke has granted the representative of the underwriters a 30 day option to purchase up to 315,000 additional shares of common stock from the Company to cover over-allotments, if any. Shares of Evoke's common stock have been approved for listing on the NASDAQ Capital Market under the symbol "EVOK" and are expected to begin trading on September 25, 2013.
The offering is expected to close on September 30, 2013, subject to customary closing conditions.
Aegis Capital Corp. is acting as sole book-running manager for the offering.
Cantor Fitzgerald & Co. and Feltl and Company, Inc. are acting as co-managers for the offering.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on September 24, 2013.
This offering is being made only by means of a prospectus. Copies of the prospectus relating to this offering may be obtained by contacting Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY 10019, telephone: 212-813-1010, e-mail: [email protected]
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Evoke Pharma, Inc.
Evoke Pharma is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. Diabetic gastroparesis is a GI disorder afflicting millions of sufferers worldwide, in which the stomach takes too long to empty its contents resulting in serious digestive system symptoms. Metoclopramide is the only product currently approved in the United States to treat gastroparesis, and is currently available only in oral and intravenous forms. EVK-001 is a novel formulation of this drug, designed to provide systemic delivery of metoclopramide through intranasal administration.
CONTACT: Investor Contact: The Ruth Group Stephanie Carrington Tel: 646-536-7017 [email protected] Media Contact: The Ruth Group Aaron Estrada Tel: 646-536-7028 [email protected]